Bangladesh ordered 25 Boeing planes in effort to lower tariffs, Reuters says
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
NeuroScientific Biopharmaceuticals (ASX:NSB) jumps 14% this week, though earnings growth is still tracking behind one-year shareholder returns
While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock market. When you buy and hold the right company, the returns can make a huge difference to both you and your family. For example, the NeuroScientific Biopharmaceuticals Limited (ASX:NSB) share price is up a whopping 576% in the last 1 year, a handsome return in a single year. Also pleasing for shareholders was the 410% gain in the last three months. The longer term returns have not been as good, with the stock price only 6.4% higher than it was three years ago. We love happy stories like this one. The company should be really proud of that performance! On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During the last year NeuroScientific Biopharmaceuticals grew its earnings per share (EPS) by 54%. The share price gain of 576% certainly outpaced the EPS growth. So it's fair to assume the market has a higher opinion of the business than it a year ago. The fairly generous P/E ratio of 70.06 also points to this optimism. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). This free interactive report on NeuroScientific Biopharmaceuticals' earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further. A Different Perspective We're pleased to report that NeuroScientific Biopharmaceuticals shareholders have received a total shareholder return of 576% over one year. That's better than the annualised return of 1.2% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 4 warning signs we've spotted with NeuroScientific Biopharmaceuticals (including 2 which are potentially serious) . For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
24 minutes ago
- Business Insider
'A Delightful Shopping Experience' Andy Jassy's Alexa Plans Sink Amazon Stock (NASDAQ:AMZN)
Chalk up another example of life imitating Dilbert. About 10 years ago, the CEO came to Dilbert with what he thought was an exciting plan: put ads on the 'little spot' that remains in your vision for a few seconds after someone takes a picture with a flash. Fast forward to today, where online shopping giant Amazon's (AMZN) CEO Andy Jassy wants to slip ads into Alexa. This horrified investors, and Amazon shares plunged over 8% in Friday afternoon's trading. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Jassy noted, not unfairly, that Alexa was commonly used as a shopping tool, telling it to add things to their shopping list or placing orders through it. Thus, Jassy noted, there was room for improvement here, and started breaking down the concept. Jassy noted that Alexa+ is already free for Prime subscribers, who pay $14.99 per month, and recently added a $20 monthly subscription fee for those who are not Prime members. Jassy then advanced the idea that there could be subscription tiers later…including an ad-supported tier. Admittedly, Alexa is not ad-free as it is. There are some ads inserted between songs via the smart speaker, or a visual ad that shows up on the display device. But Jassy wants to go farther, allowing for what reports call '…an AI-generated ad that Alexa+ delivers.' There is a certain logic to it; for those who have expressed an interest in a certain product, the opportunity to pay to have your product recommended makes sense. But the results might be inherently tainted, as customers would know the recommendation is bought and paid for. Bond To Come Amazon is also stretching its legs as a filmmaker thanks to its MGM connection. Jassy also pointed out that James Bond is now in Denis Villeneuve's hands, and that the legendary filmmaker should be able to do the project justice. Jassy noted, 'We cannot wait to get started on 007's next adventure.' Villeneuve was tasked with the project back in June, and a recent report revealed who has the screenplay duty: none other than Peaky Blinders creator Steven Knight. This was not the only advance Amazon had to offer in video recently, as it also showed off the Prime Video NBA broadcast team, featuring major names like Dwyane Wade, Kevin Harlan, and several more. Is Amazon a Good Long-Term Investment? Turning to Wall Street, analysts have a Strong Buy consensus rating on AMZN stock based on 42 Buys and one Hold assigned in the past three months, as indicated by the graphic below. After a 39.43% rally in its share price over the past year, the average AMZN price target of $262.10 per share implies 21.31% upside potential.
Yahoo
38 minutes ago
- Yahoo
Trump: Aug. 1 tariff deadline ‘stands strong'
President Trump on Wednesday indicated there would be no extensions of the deadline at the end of the week, when steep tariffs are set to go into effect on many nations. 'The August first deadline is the August first deadline — It stands strong, and will not be extended. A big day for America!!!' Trump posted on Truth Social. Trump has issued letters to more than a dozen countries informing them of tariff rates they will face to export their goods into the United States beginning Aug. 1. Those include a 25 percent tariff on India, a 35 percent tariff on Bangladesh and a 50 percent tariff on Brazil, among others. The White House has struck deals with a handful of other countries to set lower tariff rates, including with Japan, the European Union, Indonesia and the United Kingdom. Critics have argued the details around those agreements are still scarce and have noted that the tariff rate those countries will pay, while lower than an initial threat, is still higher than it was before Trump took office. The timing and severity of tariffs on other nations have been shifting targets since Trump took office, after he vowed on the campaign trail to aggressively impose duties on imports. He has repeatedly threatened tariffs on other nations, only to back off or delay their imposition. The president on April 2 announced 'reciprocal' tariffs on dozens of other countries, using trade deficits to help calculate the tariff rate. But a week later, he lowered those rates to 10 percent for 90 days as markets reacted negatively, giving time for negotiations. The 90-day window was set to expire in early July, only for Trump to set a new deadline of Aug. 1. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
